Aug 14th 2012 - Edison Investment Research today published a report on OncoGenex Pharmaceuticals entitled "Expanding Opportunities". In summary, the report says:
The development programme for OncoGenex’s lead product custirsen is gaining momentum. OncoGenex and its partner Teva will initiate the ENSPIRIT Phase III trial in second-line non-small cell lung cancer (NSCLC) later this year. They have just initiated patient enrolment to the AFFINITY Phase III study in second-line castration resistant prostate cancer (CRPC) and the registrational SYNERGY Phase III trial in first-line CRPC remains on track to report data in Q413. We have increased our valuation by $6m to $403m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »